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Adhesive and drug were weighed to give 
desired w/w percentage and stirred 
using industrial dissolver rig at 100oC for 
approx. 1 hour.  Adhesive was cast onto 
polyethylene sheets to give uniform 
layers and cured in an oven at 60oC with 
100% humidity for at least 24 hours. 
Patches were initially tested for drug 
uptake via extraction using THF and 
subsequent GC analysis.
Release properties were tested using a 
Franz-type diffusion cell, using pig skin 
as the membrane and PBS (pH 7.4) as a 
receptor medium.2 The size of the patch 
used in each case was 5cm in diameter 
or 19.6cm2. The amount of drug diffusing 
across the membrane was determined 
by monitoring the integral of the 
corresponding peak in HPLC*. 
*HPLC was run in 60/40 acetonitrile with a flow rate of 1 mL/min and detection at 225nm
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Transdermal drug delivery systems are 
widely used as an alternative to oral 
delivery. Many different types have been 
developed and numerous drugs have been 
approved for use in transdermal systems.1
We wished to develop and test 
methodologies to manufacture drug 
patches from a novel adhesive developed 
by Bostik. 
The objective of this research was to 
determine whether single-layer, drug-in-
adhesive transdermal patches could be 
produced using the adhesive  with simple 
drugs, and further to monitor the rate of 
drug delivery from the patch across the 
skin. 
• Patches were produced containing the drugs ibuprofen and diclofenac sodium 
of varying concentrations.
• Proof that drug was dissolved into the adhesive was obtained by comparing 
the GC traces of the pure drug to that extracted from the patch via THF. This 
was further proved by GCMS.
• An example using ibuprofen is shown in figure 3, where the corresponding 
ibuprofen peaks (~5.15 mins) suggest ibuprofen was present in the adhesive. 
This was later confirmed by mass spectrometry.
Conclusions
• Methodology was developed to produce drug-containing patches of the 
adhesive using some bioavailable drugs and with varying concentrations of 
those drug. 
• Proof by HPLC that drug is able to be provided by patches in a controlled 
release manner across the skin. 
• Adhesive could potentially provide alternatives to current transdermal patches 
as it provides very slow release across the skin for small doses of drug.
Future Outlook
• Future research should focus upon the release properties of more complex 
and pharmacologically valuable drug molecules.
• Research should also be undertaken concerning the viability of upscaling or 
mass producing drug patches based upon the methodologies described here.
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Figure 3 GC chromatograms of ibuprofen (left) and adhesive containing
ibuprofen (right), with an eluent of THF.
Figure 4 Plot of HPLC integral of the ibuprofen peak of the receptor
medium against time of exposure of the receptor medium to the skin
with transdermal patch for different concentrations of drug.
• HPLC data proved that patch could deliver drug across the skin via diffusion, 
as HPLC integral is proportional to amount of drug. 
• Increasing the amount of drug in the adhesive increased the amount and rate 
of drug delivery (figure 4). 
• Rate of drug delivery was much slower than the commercial ibuprofen gel 
(figure 5), indicating it could be effective as a slow controlled delivery system 
for specific applications.
• From a calibration curve, it was estimated that ~0.5mg of  ibuprofen was 
delivered by the 32.3% w/w patch over 24 hours. This suggested the adhesive 
would be most appropriate for delivery of drugs requiring only small doses, 
such as fentanyl.3
Figure 5 Plot of HPLC integral against exposure time comparing a
commercially available 5% w/w gel (standard dosage) with the adhesive
patches
Figure 1 Experimental setup for
manufacturing patches (left) and
cured adhesive patch (right)
Figure 2 Experimental setup for
monitoring drug release properties
